Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases Our initial focus is on the treatment of Interstitial Lung Diseases, including Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.

Avalyn is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other Interstitial Lung Diseases (ILD). ILDs are characterized by pulmonary scarring, a decline in lung function, reduced exercise capacity and quality of life, and increased mortality risk. Currently approved therapeutic options slow disease progression but are associated with significant side effects, which restrict their use and dosing. Avalyn is developing a pipeline of new inhaled formulations of approved oral medicines designed to reduce systemic exposure and deliver medication to the site of disease. Avalyn’s pipeline is led by AP01, an optimized inhaled formulation of pirfenidone, which has been assessed in 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with improved efficacy and safety over existing therapies.

Learn more about this approach and our therapeutic focus.

Lyn Baranowski photo

Lyn Baranowski

Chief Executive Officer

Doug Carlson photo

Doug Carlson

Chief Financial Officer and Chief Business Officer

Melissa Rhodes, Ph.D., D.A.B.T photo

Melissa Rhodes, Ph.D., D.A.B.T

Chief Operating Officer

Howard M. Lazarus, M.D., FCCP photo

Howard M. Lazarus, M.D., FCCP

Chief Medical Officer

Mark Surber, Ph.D. photo

Mark Surber, Ph.D.

Founder and Chief Scientific Officer

Jim Bishop photo

Jim Bishop

Senior Vice President, Business Operations

Craig Conoscenti, M.D., FCCP, ATSF photo

Craig Conoscenti, M.D., FCCP, ATSF

Senior Vice President, Clinical Development

Michelle Patterson photo

Michelle Patterson

Senior Vice President, Program Management

Stephen Pham, Ph.D. photo

Stephen Pham, Ph.D.

Senior Vice President, Product Development

Niall O’Donnell, Ph.D. photo

Niall O’Donnell, Ph.D.

Chairman, Managing Director, RiverVest Venture Partners

Tiba Aynechi, Ph.D. photo

Tiba Aynechi, Ph.D.

General Partner, Norwest Venture Partners

Scott A. Beardsley photo

Scott A. Beardsley

Managing Partner, Novo Ventures (US), Inc

Jill Carroll photo

Jill Carroll

Partner, SR One

Gianna Hoffman-Luca, Ph.D. photo

Gianna Hoffman-Luca, Ph.D.

Principal, Perceptive Xontogeny Venture Funds

Jonathan Leff, M.D. photo

Jonathan Leff, M.D.

Independent Director

Ketan Patel, M.D. photo

Ketan Patel, M.D.

Partner, F-Prime Capital

Lyn Baranowski photo

Lyn Baranowski

Chief Executive Officer

Andera Partners Investor Logo
F/Prime Investor Logo
Norwest Investor Logo
Novo Investor Logo
Pivotal Bioventure Partners Investor Logo
Rivervest Investor Logo
TPG Investor Logo


With family history of IPF, Founder Mark Surber conceives of inhaled pirfenidone (AP01)


First AP01 Patent Filed &

Avalyn Incorporated


First AP01 Publication

AP01 US Orphan Drug Designation for the treatment of IPF


$62M Series A Complete


AP01 Phase 1a Complete


First Inhaled Nintedanib (AP02) Publication

$35M Series B Complete


AP01 Phase 1b POC Complete

AP02 Phase 1a Complete

AP01 EU Orphan Drug Designation for the treatment of IPF


AP01 Phase 2b Design
$175M Series C Complete